Fate Therapeutics (FATE) collapses 55% after terminating Janssen deal, earns several downgrades
Tweet Send to a Friend
Shares of Fate Therapeutics (NASDAQ: FATE) are down more than 56% in pre-market after the company said it has declined ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
